NIH researchers define local diagnostic criteria for withdrawal of steroids

Scientists from the National Institutes of Health (Nih) have determined that dermatitis resulting from local withdrawal of steroids (TSW) differs from eczema and is caused by the excess of the necessary chemical in the body. Scientists at the NIH National Institute of Allergy and Infectious Diseases (NIAID) identified treatment methods that could be examined in clinical studies on the condition based on their potential levels⁺), form of vitamin B3. The discoveries were published today in.

Dermatitis is characterized by inflammationItching or burning sensations on the skin and may result from various conditions, including TSW and eczema. Eczema, also known as atopic dermatitis, is a common cause of dermatitis and affects 10 to 30% of children and 2 to 10% of adults each year in the United States. Local steroids-especially glucocorticoids or local corticosteroids-were used to be used as a first-line treatment of skin inflammation caused by eczema, because the drugs are safe, effective, easy to use and considered well tolerated.

Some people experience dermatitis after using local steroids for a long time, and then stopping – a state called TSW. Diagnosing and treating this state is difficult because TSW is not well understood. Symptoms include redness of the skin, combustion sensations, skin heat (thermal divergence), itching and peeling, which may even occur on body parts where local steroids were not used. Because TSW and eczema have similar symptoms, it was difficult to distinguish between two disorders.

To better understand the TSW, a team led by scientists from the Niaid and microbiology clinical immunology laboratory assessed the previous study in which it included 1,889 adults with symptoms similar to eczema. By dividing participants into people with and without TSW reported by them, scientists identified unique features for TSW. Then scientists conducted a pilot study, including 16 people with symptoms in line with TSW, 10 people with eczema, but without TSW symptoms and 11 people without skin diseases. Have found that people with TSW symptoms had an increased level above⁺ in blood serum and skin, while above⁺ The levels were in a typical range in people without TSW symptoms.

Then scientists used bred skin cells and a mouse model to follow TSW conditions. They discovered that over⁺ It was produced in response to local steroids and caused inflammation. The models suggested that the drug that blocked the formation above⁺– he looked at the mitochondrial complex – would improve the symptoms of TSW. In a pilot study, in order to further assess this strategy, scientists assessed subjective answers among research participants who used the mitochondrial complex of metformin, barberine or both. After three to five months of use, most participants reported an improvement in TSW symptoms.

Scientists temporarily established criteria that can be used by healthcare professionals to identify TSW in humans. People who have detained local steroid treatment and meet the criteria can diagnose practitioners as TSW. Scientists suggest that patients identified as having TSW can be treated using the proposed mitochondrial complex locking drugs I.

The results of this study can help doctors identify TSW in patients and work on the development of safe and effective treatment methods. According to scientists, further research is needed to determine whether all patients from TSW have excess above⁺or if there are other functions defining TSW. In addition, diagnostic criteria will help healthcare providers and researchers to better understand the frequency of TSW and assess the effects of the use of local steroids.